Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Acrux Limited ( (AU:ACR) ) just unveiled an announcement.
Acrux Limited announced the approval and launch of its Nitroglycerin 0.4% Ointment in December 2024, alongside ongoing preparations for launching Dapsone 7.5% Gel and expanding the Dapsone 5% Gel range. These activities are part of Acrux’s strategy to enhance its portfolio of revenue-generating products. The company also completed a successful Placement and Share Purchase Plan, raising $3.99 million, and reported positive cash inflows from operating activities for the December quarter. This financial boost is expected to support Acrux’s future product development and growth ambitions.
More about Acrux Limited
Acrux Limited is a specialty pharmaceuticals group based in Melbourne, Australia. The company focuses on developing and commercializing topical generic products, including nitroglycerin ointments and dapsone gels, aimed at generating sustainable and growing revenues.
YTD Price Performance: 0.0%
Average Trading Volume: 500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.27M
For an in-depth examination of ACR stock, go to TipRanks’ Stock Analysis page.
